Form D · Biotechnology
Manifold Biotechnologies, Inc.
Boston, MA · CIK 0001820326
Offering snapshot reported Dec 3, 2024 · SEC filing
- Reported sold
- $32.8M Offering amount: $32.8M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 18, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 3, 2024 | Initial | $32,784,801 | No comparison | 10 | SEC filing |
| Jun 13, 2022 | Initial | $39,999,985 | No comparison | 13 | SEC filing |
| Aug 13, 2020 | Initial | $5,400,694 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-530923
The Total Offering Amount and Total Amount Sold include the aggregate exercise price of certain warrants to purchase shares of capital stock of the Issuer.
Source: Form D, filed Dec 3, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jory Bell | Director |
| Steven Holtzman | Director |
| Jeff Huber | Director |
| Steven J. Kafka | Director |
| Gleb Kuznetsov | Director, Executive |
| Pierce Ogden | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
201 Brookline Avenue Suite 902
Boston, MA, 02215
Boston, MA, 02215